Paysign, Inc. is a vertically integrated provider of prepaid card products and processing services for corporate, consumer, and government entities. Incorporated in 1995, the company operates as a payment processor and prepaid card program manager, deriving revenue from all stages of the prepaid card lifecycle. Its product suite includes corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments, and pharmaceutical payment assistance. The company also offers life science technology solutions targeting blood and plasma collection organizations under the Apherion brand, generating revenue through licensing, hosting, and consulting fees. Paysign serves customers in the healthcare, pharmaceutical, and source plasma industries, as well as small and medium-sized businesses, Fortune 500 companies, multinationals, universities, and social media companies. Its cards are sponsored by issuing bank partners, including Patriot Bank, N.A., and carry network brands such as Visa. The company provides end-to-end services including card design, production, distribution, personalization, inventory management, security controls, and 24/7 bilingual customer support. Paysign’s platform supports transaction processing, cardholder enrollment, value loading, account management, data analytics, and customer service, with API-based solutions for integration into client systems.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Financial Data & Stock Exchanges Homepage paysign.com
Sector Financial Services IR page paysign.com/investors
Tags
prepaid cards, payment processing, corporate rewards, pharmaceutical payment assistance, plasma donation, digital banking, employee incentives, gift cards, clinical trials, healthcare reimbursement, Paysign, Apherion, Paysign Premier, Paysign Patient Affordability Solutions, Paysign Disbursement Solutions, Paysign Incentive Solutions, Patriot Bank N.A., Visa
Press page paysign.com/news-media

Metrics

Valuation  
Market cap $ 528.376M
Market cap (USD) $ 528.376M
P/E 28.17
PEG 0.30
P/BV 7.96
P/S 4.81
P/OCF 4.04
P/FCF 4.07
Dividend yield —
Turnover / mcap —
Returns  
ROE 19.1%
ROI 13.4%
ROIC 9.8%
Profit margin 9.2%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 94.4%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 8.1%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 24
Quality score 47.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Revenue 82.028M 58.385M 47.274M 38.034M 29.465M 24.12M 34.667M 23.424M 15.234M 10.417M 8.108M 10.293M 6.308M 6.7M 3.3M 4.348M 4.201M
Net profit 7.552M 3.816M 6.459M 1.028M -2.721M -9.142M 7.454M 2.588M 1.791M 1.401M -2.41M 2.61M 611.684K 1.817M 215.291K -8.292K -96.14K
Free cash flow 51.242M 22.512M 27.358M 25.213M 14.9M 12.393M 16.249M 15.739M 6.444M 1.157M -857.836K 2.942M -672.604K 1.979M 186.992K 61.337K -300.417K

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Share price 5.15 3.02 2.8 2.58 1.6 4.64 10.15 — — — — — — — — — —
Price performance 12m 0.71 0.08 0.09 0.61 -0.66 -0.54 — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 110,269 165,523 337,303 891,936 654,859 3.39M 4.68M 16.2M 32.6M 72.2M
↳ YoY growth +558.6% +50.1% +103.8% +164.4% -26.6% +418.3% +37.9% +246.6% +101.2% +121.2%
↳ 5y CAGR -38.5% +15.3% -2.9% +59.4% +108.2% +98.4% +95.1% +117.0% +105.4% +156.1%
Borrowings, current (USD) — — — — — — — — 0.00 1.86M
Borrowings, non-current (USD) 27,892 0.00 — — — — — — 0.00 6.14M
Lease liabilities (USD) — — — 0.00 4.33M 4.01M 3.67M 3.31M 2.93M 6.03M
Cash and deposits (USD) 11.6M 17.2M 31.7M 45.6M 55.9M 7.39M 89.9M 109M 122M 165M
Intangible assets (USD) 1.55M 1.64M 2.12M 3.82M 3.7M 4.09M 5.66M 8.81M 12.2M 22.3M
Right-of-use assets (USD) — — — 0.00 4.32M 3.99M 3.61M 3.22M 2.79M 5.73M
Net debt (borrowings + leases - cash) (USD) -11.6M -17.2M — — — — — — -119M -151M
Cash flow detail
Operating cash flow (USD) 1.27M 7.15M 16M 16.7M 13.8M 15.2M 25.3M 27.6M 22.9M 52.5M
Purchases of property, plant and equipment (USD) -109,865 -707,224 -257,062 -463,714 -1.38M -328,566 -105,186 -262,556 -434,901 -1.21M
Purchases of intangible assets (USD) -777,144 -812,122 -1.34M -2.77M -81,261 -62,418 -185,000 0.00 -127,600 -83,401
Change in receivables (cash effect) (USD) -93,527 -55,254 -171,780 -554,633 237,077 -2.88M -1.29M -11.5M -16.4M -39.6M
Change in payables (cash effect) (USD) 415,504 379,487 182,414 196,107 741,533 3.6M 2.32M 18.5M 7.81M 36.6M
Share buybacks (cash effect) (USD) — — — — — — 0.00 -1.13M -495,045 -375,786
Interest paid (cash effect) (USD) -77,107 -46,663 0.00 0.00 0.00 -4,587 -221 0.00 0.00 —
Income taxes paid (cash effect) (USD) 0.00 -16,200 -7,504 0.00 0.00 -4,073 -35,949 -207,945 -136,631 -414,186
Share-based compensation (USD) 92,939 308,696 1.37M 2.53M 2.97M 2.28M 2.28M 2.85M 2.6M 4.26M
Operating cash flow before change in receivables (USD) 1.36M 7.21M 16.2M 17.3M 13.5M 18.1M 26.6M 39.2M 39.4M 92M
Free cash flow (OCF - PPE - intangibles) (USD) 379,714 5.63M 14.4M 13.5M 12.3M 14.8M 25M 27.4M 22.4M 51.2M
Reported Mar 26, 2018 Mar 26, 2018 Mar 12, 2019 Aug 14, 2020 Mar 23, 2022 Mar 23, 2022 Mar 27, 2024 Mar 27, 2024 May 9, 2025 Mar 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Patient Affordability Growth Drives Revenue and Margin Expansion

Raises Full Year 2026 Gross Margin, Net Income, GAAP EPS and Adjusted EBITDA Guidance

Balance Sheet Supports Continued Investment and Growth Initiatives

HENDERSON, Nev. – November 9, 2026 – (Business Wire) – Paysign, Inc. (NASDAQ: PAYS), a provider of patient affordability offerings, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, today announced financial results for the third quarter 2026.

Third Quarter 2026 Financial Highlights

· Revenues of $30.80 million in Q3’26, up 42.6% from Q3’25

· Pharma revenue increased 109.8% to $16.62 million in Q3’26 versus Q3’25; added 62 net patient affordability programs during the past 12 months, exiting the quarter with 167 active programs

· Plasma revenue increased 7.5% to $13.83 million in Q3’26 versus Q3’25; total net plasma center count decreased by 33 during the past 12 months, exiting the quarter with 562 centers

· Gross profit margin was 64.7% in Q3’26 compared to 56.3% in Q3’25; operating margin increased to 23.8% in Q3’26, up from 7.3% in Q3’25

· GAAP net income of $6.74 million,

Paysign to Host Third Quarter 2026 Earnings Call Bull 0 Bear 0 Routine

News & Media

Categories

Archives

HENDERSON, Nev. – October 13, 2026 – (Business Wire) – Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, will discuss third quarter 2026 earnings at 5:00 p.m. Eastern time on Monday, November 9, 2026.

Participant details are as follows: U.S. dial-in: 877.407.2988 International dial-in: +1.201.389.0923 Webcast: Click Here

Replay: Dial-in: 877.660.6853 or +1.201.612.7415 Conference ID: 13763287

The replay will be available until January 25, 2027.

To register as a financial professional in order to ask questions during the call, please email [email protected] no later than 5:00 p.m. Eastern time on Friday, November 6, 2026.

About Paysign

Paysign, Inc. (NASDAQ: PAYS) operates at the intersection of fintech and healthcare, integrating advanced payment processing and program management with tailored technologies for the plasma, pharmaceutical and life sciences industries. Their breakthrough patient affordability solutions ensure patients receive the financial assistance they need to adhere to prescribed therapies by mitigating the effects of copay accumulators and maximizers. Paysign specializes in blood and plasma donor compensation programs, as well as comprehensive engagement and management platforms optimized for life sciences. Paysign’s proprietary processing architecture supports physical, virtual, mobile and bank-based payments with real-time transaction intelligence, enabling efficient, compliant and scalable program delivery. Through advanced reporting, analytics and in-house 24/7 bilingual customer support, Paysign delivers measurable value, exceptional service and a superior experience for donors, patients, healthcare providers, pharmaceutical manufacturers and program sponsors across their growing fintech healthcare ecosystem. The company is committed to improving efficiencies, reducing costs, streamlining communications, increasing program performance and providing actionable insights to those they serve.

Forward-Looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the companies, are forward-looking statements that involve risks and uncertainties. There is no assurance that such statements will prove to be accurate, and actual results and future events could differ materially. Paysign undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

News & Media

Categories

Archives

Paysign will be a sponsor at the Plasma Protein Therapeutic Association Forum in Alexandria, VA, on November 3-4, 2026. This annual conference brings together policymakers, industry leaders, healthcare professionals and patients together to learn more about key developments and current issues within the plasma industry.

Prompts

Paysign, Inc. (ticker PAYS), listed in United States.

Company History

Date Change Detail
Apr 11, 2019 Renamed 3PEA INTERNATIONAL, INC. → PAYSIGN, INC.

ETFs Holding Paysign, Inc.

ETF Weight in ETF Shares Market value As of
MGMT 1.49% 325,376 $ 2.665M Jun 30, 2026
EHLS 0.47% 26,649 $ 254.231K Nov 17, 2026
LITL 0.38% 2,210 $ 21.68K Nov 17, 2026
SQLV 0.18% 6,213 $ 50.884K Jun 30, 2026
VFQY 0.07% 29,160 $ 363.334K Aug 31, 2026
VFMO 0.04% 59,000 $ 735.14K Aug 31, 2026
AVSC 0.02% 69,309 $ 661.208K Nov 16, 2026
RESM 0.02% 80 $ 655.20 Jun 30, 2026
DFAS 0.01% 326,247 $ 3.096M Nov 12, 2026
DXUV 0.00% 22,458 $ 213.126K Nov 12, 2026
MSSM 0.00% 1,556 $ 19.388K Aug 31, 2026
DCOR 0.00% 58,512 $ 555.279K Nov 12, 2026
DFUS 0.00% 17,165 $ 162.896K Nov 12, 2026
DFAU 0.00% 9,350 $ 88.732K Nov 12, 2026
DFAC 0.00% 60,802 $ 577.011K Nov 12, 2026
EBI 0.00% 61 $ 760.06 Aug 31, 2026
DFSU 0.00% 8 $ 75.92 Nov 12, 2026
AVUS 0.00% 40,381 $ 385.235K Nov 16, 2026
AVUV 0.00% 12,819 $ 122.293K Nov 16, 2026
AVSU 0.00% 697 $ 6,649.38 Nov 16, 2026